Tuberculosis in an inflammatory bowel disease cohort from South Africa

South African Medical Journal

Volumn 102, Issue 10, 2012, Pages 802-804

  Deetlefs, E ^a   Epstein, D ^a   Watermeyer, G A ^a   Seggie, R M ^a   Thomson, S R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; CROHN DISEASE; DATA BASE; DISEASE ASSOCIATION; ENTERITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; SOUTH AFRICA; THORAX RADIOGRAPHY; TUBERCULOSIS; ULCERATIVE COLITIS;

ADULT; COMORBIDITY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS; YOUNG ADULT;

EID: 84867440104     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.5609     Document Type: Article

References (16)

1. World Health Organization (WHO). Global Tuberculosis Control 2009: Epidemiology, Strategy and Financing. WHO/HTM/TB/2009. Geneva: WHO, 2009.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on a systemic review. Gastroenterology 2012;142(1):46-54. [http:// dx.doi.org/10.1053%2Fj.gastro.2011.10.001]
3. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010;11(3):134-147. [http://dx.doi.org/10.1111%2Fj.1751-2980.2010.00429.x]
4. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133(1):312-39. [http://dx.doi.org/10.1053%2Fj. gastro.2007.05.006]
5. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106(2):199-221. [http://dx.doi.org/10.1038%2Fajg.2010.392]
6. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16(1):112-124.[http:// dx.doi.org/10.1002/ibd.21048]
7. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-936. [http://dx.doi.org/10.1053%2Fj. gastro.2008.01.012]
8. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140(6):1827-1837. [http://dx.doi.org/10.1053%2Fj.gastro.2011.02.045]
9. Zabana Y, Domenech E, San Roman AL, et al. Tuberculosis chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008;14(10):1387-1391. [http://dx.doi.org/10.1002%2Fibd.20496]
10. Mahomed H, Hawkridge T, Verver S, et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis 2011;15(3):331-336.
11. Centers for Disease Control and Prevention. Instructions to Panel Physicians for Completing Chest X-ray and classification worksheet (DS-3024). http://en.wikipedia.org/wiki/Tuberculosis_radiology (accessed 8 January 2012).
12. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43(8):948-954. [http://dx.doi.org/10.1080%2F00365520801957149]
13. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PloS Med 2007;4(1):e20. [http://dx.doi.org/10.1371%2Fjournal. pmed.0040020]
14. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors and the risk of tuberculosis. Arthritis Rheum 2006;55(1):19-26. [http://dx.doi.org/10.1002%2Fart.21705]
15. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4(5):621-630. [http:// dx.doi.org/10.1016%2Fj.cgh.2006.03.002]
16. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345(15):1098-1104. [http://dx.doi.org/10.1056%2FNEJMoa011110]